Zoo Knoxville welcomes new litter of bat-eared fox kits
KNOXVILLE, Tenn. (WATE) — Zoo Knoxville is now home to six more bat-eared foxes, with the second litter to a pair of parents being born at the end of April.
According to Zoo Knoxville, the six kits, two males and four females, were born on April 30. This is the second set of bat-eared fox kits from mother Motsumi and father Fern, who welcomed their first kit, Ziggy, in 2024. Zoo Knoxville said all six kits are thriving and have begun eating solid food.
Zoo Knoxville welcomes two new rhinos ahead of new exhibit opening
'This is one of the largest litters of bat-eared foxes born in human care in the country, and we are thrilled with how well all six kits are doing,' said Terry Canon, Head Curator of Carnivores. 'Fern and Motsumi are showing outstanding parental instincts. They are working closely together to care for and protect their young.'
Zoo Knoxville said both parents are working together and providing excellent care for their growing family. The kits recently had a wellness check with the zoo's veterinary team, and while they are being monitored closely, human interaction is being kept to a minimum to allow the kits to bond with their family naturally.
Guests may soon be able to spot the kits during the early mornings and later afternoons as they venture out of the den.
Zoo Knoxville welcomes litter of endangered red wolf pups
Bat-eared foxes play a vital role in controlling insect populations in the more than 10 African Countries they are native to. Annually, one bat-eared fox can consume more than a million termites.
Zoo Knoxville said while the species is not endangered, they are increasingly impacted by habitat loss and human-wildlife conflict.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Mesker Park Zoo puts its tortoises on display
HENDERSON, Ky. (WEHT) — Mesker Park Zoo in Evansville moved its tortoises outside for the season. Zoo officials say they weighed all the tortoises and put them on display. African spurred tortoises can go weeks without food or water. Experts say they can drink up to 15 percent of their body weight when they find a water source. They can also live up to 100 years old. Mesker Park Zoo is open all year long. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
WH budget chief pressed on PEPFAR funds, says Africa ‘needs to absorb more of the burden'
Office and Management Budget Director Russell Vought on Wednesday was pressed on proposed cuts to the President's Emergency Plan for AIDS Relief (PEPFAR) pursued as part of a new rescissions request from the Trump administration. During a budget hearing Wednesday, Vought defended proposed reductions as targeting items like 'teaching young children how to make environmentally friendly reproductive health decisions' and efforts he claimed were aimed at strengthening 'the resilience of lesbian, gay, bisexual, transgender, intersex and queer global movements.' 'We can find waste, fraud and abuse there that the American people would not support, and it's one of the reasons why it's in the package, but it will not lead to life saving treatment being denied,' he said during the hearing. Congress, under the Biden administration, appropriated approximately $7 billion for PEPFAR in fiscal 2024. The program is considered to be one of America's most consequential programs in Africa and is credited with saving 25 million lives and scaling back the AIDS epidemic. During the hearing, Rep. Mark Alford (R-Mo.) in a follow-up question pressed Vought again about his comments and potential cuts to prevention efforts. 'Aside from the crazy woke programs, which I agree should be stripped,' Alford asked, 'is there any other prevention program, not treatment, but prevention program listed in this rescission package, which is not of a woke nature?' Vought said in response that the administration seeks to scale 'down the program as it pertains to the types of organizations that are providing the examples of the waste, fraud and abuse.' But he also said 'the prevention itself is where an analytical look needs to be done.' 'There's life saving treatment after you already have HIV, but there are prevention programs that PEPFAR does, which are not of the woke nature, which can prevent someone from getting HIV,' Alford countered. 'Are those programs going to survive?' 'It is something that our budget will be very trim on because we believe that many of these nonprofits are not geared toward the viewpoints of the administration, and we're $37 trillion in debt,' Vought responded. 'So, at some point, the continent of Africa needs to absorb more of the burden of providing this health care.' The moment comes as the prospect of PEPFAR cuts has prompted concern from some congressional Republicans as part of a larger request sent by the Trump administration to cut more than $9 billion in congressionally approved funds for foreign aid and public broadcasting programs. Senate Appropriations Committee Chair Susan Collins (R-Maine) has also voiced opposition to cutting PEPFAR, saying Wednesday that the idea makes 'no sense' to her 'whatsoever.' 'Given the extraordinary record of PEPFAR in saving lives, it has literally saved millions of lives, and so I do not see a basis for cutting it,' she said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
an hour ago
- Yahoo
0602K + Tirzepatide Muscle Mass / Function and Adipose Transformation Data to be Presented at ADA Scientific Sessions
GRAND RAPIDS, Mich., June 4, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., developing innovative therapies for patients suffering from diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced that new preclinical data combining lead candidate 0602K and tirzepatide as a late-breaking poster will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions, taking place June 20–23, 2025, at McCormick Place Convention Center in Chicago, Illinois. Presentation details: Title: 1982-LB - MPC-Directed Insulin Sensitizer MSDC-0602K Combines with Tirzepatide to Maintain Muscle Mass/Function and Restructure Adipose Tissue [Board No. 1982] Authors: M. Abu-Farha, J. Abubaker, F. Almulla, M. Abdul-Ghani, L. Norton, R.A. DeFronzo,J.R. Colca, K.S. McCommis Date & Time: Sunday, June 22, 2025, at 12:30 AM CT Location: Poster Hall (Hall F1) The abstract for this late-breaking poster will be available beginning Friday, June 20, 2025 at 6:30 PM CT. About CiriusCirius is a clinical-stage pharmaceutical company focusing on mitochondrial pyruvate carrier (MPC), addressing the metabolic dysfunction that causes insulin resistance and the organ pathologies associated with type 2 diabetes (T2D) and obesity/overweight. Its lead product candidate, 0602K (azemiglitazone potassium), is a potential best-in-class small molecule being developed as a once-daily oral therapy designed to selectively inhibit the mitochondrial target MPC, which plays a central role in selecting mitochondrial energy substrates. MPC inhibition reprograms mitochondrial metabolism, reducing insulin resistance in cells and driving metabolic benefits in organs throughout the body. This markedly improves glycemic control in T2D, body composition in obesity, liver function and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), and outcomes in cardiometabolic disorders. About 0602K0602K has completed 7 US clinical trials including a 52-week placebo-controlled Phase 2b study in 392 subjects with MASH with and without T2D, and a 28-day placebo-controlled Phase 2a study in 129 subjects with T2D. In those clinical studies it markedly lowered HbA1c and insulin levels, and reduced liver injury and MASH – including on top of existing GLP-1 therapy. Preclinical studies also demonstrate increased lean muscle mass and function, together with marked metabolically beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), including increased brown adipose tissue ("brown fat"). Selectively targeting MPC – while avoiding PPAR-γ activation – 0602K harnesses the real-world proven efficacy of 1st generation insulin sensitizers, such as pioglitazone, but without their side effect concerns. Directly correcting a major underlying pathophysiology of chronic metabolic disease, 0602K has the potential to become a cornerstone of therapy. Coupling this potent pharmacology with that of the GLP-1s could particularly benefit patients with T2D, obesity/overweight and other diseases. View original content to download multimedia: SOURCE Cirius Therapeutics
